{"time":1700070081938,"blocks":[{"type":"paragraph","data":{"text":"Cole, who has 25-plus years of biopharmaceutical R&D\nexperience and was previously SVP and Head of Chemistry for 1910, will lead the\ncompany’s research in small and large molecule\ndrug discovery"}},{"type":"paragraph","data":{"text":"BOSTON – November 16, 2023 – 1910 Genetics, the only biotech advancing small and\nlarge molecule drug discovery with an automated, multimodal AI platform, today\nannounced the appointment of Bridget Cole to\nChief Scientific Officer. Cole, who previously\nserved as SVP and Head of Chemistry,\nwill lead the biotech’s scientific research operations, set and advance\nresearch priorities, and work closely with 1910’s AI leadership to guide model and platform\ndevelopment with her drug development expertise. "}},{"type":"paragraph","data":{"text":"Cole has over 25 years of drug\ndiscovery and clinical development experience, helping advance compounds from\nlead identification through late-stage clinical trials across a wide range of\ntherapeutic areas. Her background as a chemist and leader of medicinal\nchemistry teams has made her a critical part, and cultural fit, for 1910\nGenetics which is focused on generating drugs with both an optimal\npharmacological profile and molecular basis determined upfront. "}},{"type":"paragraph","data":{"text":"“Our ambition to generate small\nand large molecule drugs, using a multimodal AI and data-intensive platform,\nrequires a seasoned but progressive drug developer and team leader like\nBridget,” said Jen Nwankwo, Ph.D.,Founder and\nCEO. “As Chief Scientific Officer, Bridget will take over additional\nresearch responsibilities internally and externally, engage directly with\npartners on scientific R&D, and support our vision to become the next\nGenentech – a true innovator in advancing modern drug discovery.” "}},{"type":"paragraph","data":{"text":"Before 1910 Genetics, Cole was SVP\nof Drug Discovery at Nocion Therapeutics where she led lead optimization\nprograms to develop novel therapies for conditions associated with neurogenic\ninflammation, including a phase 2 drug candidate for chronic cough. Prior to\nNocion, Cole held several biopharmaceutical R&D leadership positions\nincluding: VP of Medicinal Chemistry at Axial Biotherapeutics, where she\ndeveloped microbiome-inspired therapies for neurodegenerative conditions; VP at\nFlatley Discovery Lab, where she led discovery programs and helped develop two\nclinical candidates for cystic fibrosis; VP at Surface Logix where she directed\nmedicinal chemistry and supported development of three clinical programs; and\nAssociate Director of Chemistry at Pfizer.
\n
\nA Boston native, Cole received her bachelor's\ndegree in chemistry from Boston University, her Ph.D. in organic chemistry from\nBrandeis University, and completed postdoctoral training at Boston College. She\nis also the co-inventor on 30 issued U.S. patents. "}},{"type":"paragraph","data":{"text":"“After an already rewarding career serving companies like\nPfizer and Nocion to advance new medicines for patients, I was drawn to 1910\nGenetics because of their unique approach to leveraging both wet lab data and\nAI methodologies for drug discovery, and, importantly, their highly talented\nteam. I have never met anyone like Jen Nwankwo, and I love working with her and\nmy 1910 colleagues to develop innovative solutions to merge technology with\nempirical biology to drive drug discovery programs,” said Bridget Cole. “I look\nforward to continuing to guide and grow this team as we engineer better\ntreatments for patients and make undruggable targets a thing of the past.” "}},{"type":"paragraph","data":{"text":"Since launching in 2021, 1910 Genetics\nhas raised $26.1 million in funding from M12-Microsoft’s Venture Fund,\nPlayground Global, OpenAI CEO Sam Altman, and other leading investors. 1910 is\ncurrently one of the only biotech companies using Microsoft’s Azure Quantum\nElements to bring quantum computing power to scientific discovery. The company\ncontinues to advance a pipeline of novel drug candidates on its own and in\npartnership with pharma and tech leaders. "}},{"type":"paragraph","data":{"text":"About 1910 Genetics
\n1910 Genetics is the\nonly biotech company advancing small and large molecule drug discovery with an\nautomated, multimodal AI platform. We integrate AI with three proprietary data\nstreams – computational data, wet lab gold standard biological data and wet lab\nproxy biological data – to deliver novel drug candidates to leading pharma and\ntech partners, and advance our own pipeline for neurological, autoimmune\ndiseases, and cancer. 1910 was launched in 2021 with a combined seed and Series\nA funding of $26.1M backed by M12-Microsoft’s Venture Fund, Playground Global,\nOpenAI’s Sam Altman, and other leading investors. We have since established our\nHQ and lab facilities in Boston’s Seaport District and continue to hire a\nworld-class team. To learn more visit 1910genetics.com."}},{"type":"paragraph","data":{"text":"Media Contact: "}},{"type":"paragraph","data":{"text":"Amanda Guisbond
\nmedia@1910Genetics.com"}}],"version":"2.19.0"}

1910 Genetics Appoints BridgetCole to Chief Scientific Officer